XOOMAR

ADMA BIOLOGICS, INC. (ADMA)

Every FINRA and SEC series the site collects for ADMA BIOLOGICS, INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

22.7M

Short interest

settlement 2026-08-14

8.0

Days to cover

+3.5% vs prior

58.7%

Short share of volume

2026-09-11

384

Fails to deliver

settlement 2026-07-22

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-09-11.

Short interest

FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSON

As of 14 August 2026, short interest in ADMA is 22,683,647 shares, down 1,347,865 shares over the last month. Over the last 48 readings it ranged from 9,499,242 shares (30 August 2024) to 25,826,838 shares (13 March 2026). At the reported average volume of 2.8M shares a day that is 8.0 days to cover, elevated.

Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/adma" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-08-1422,683,647+3.5%2,843,5697.98
2026-07-3121,918,195-8.8%2,482,9678.83
2026-07-1524,031,512-0.8%2,635,9629.12
2026-06-3024,232,698+13.9%4,167,8535.81
2026-06-1521,280,060+7.0%3,277,3336.49
2026-05-2919,897,126-0.5%3,298,9816.03
2026-05-1519,994,416-3.2%8,837,1402.26
2026-04-3020,658,114+7.0%6,419,4913.22
2026-04-1519,306,519-12.9%5,025,5733.84
2026-03-3122,175,506-14.1%13,551,2471.64
2026-03-1325,826,838+35.0%3,625,7527.12
2026-02-2719,137,458-9.1%3,345,7855.72
2026-02-1321,049,574+8.3%1,790,90411.75
2026-01-3019,439,065+4.7%2,114,8609.19
2026-01-1518,573,160-2.1%2,573,7037.22
2025-12-3118,972,317+0.8%2,036,3849.32
2025-12-1518,829,424+1.4%2,592,4777.26
2025-11-2818,563,031-0.4%3,160,3415.87
2025-11-1418,629,225+11.9%4,654,7484.00
2025-10-3116,649,924-5.2%2,999,4695.55
2025-10-1517,560,695+0.9%3,572,5334.92
2025-09-3017,410,928+10.6%3,388,6005.14
2025-09-1515,740,996+5.1%3,566,1674.41
2025-08-2914,977,531+0.1%2,347,6096.38

Daily short volume

FINRA Reg SHO, last 60 sessions. JSON

As of 11 September 2026, the short share of ADMA volume is 58.7%, down 3.6 points over the last five sessions. Over the last 52 readings it ranged from 37.4% (30 June 2026) to 78.6% (11 August 2026). The latest reading is 3.8 points above the 30-session average of 54.8%, on 663K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-09-11389K663K58.7%1,800
2026-09-10374K740K50.6%0
2026-09-09435K745K58.3%0
2026-09-08400K673K59.4%0
2026-09-04272K489K55.6%0
2026-09-03284K457K62.3%1,008
2026-09-02267K597K44.7%1
2026-09-01262K652K40.2%108
2026-08-31179K434K41.1%464
2026-08-28241K463K52.2%10
2026-08-27268K467K57.4%100
2026-08-26227K433K52.4%0
2026-08-25238K416K57.3%12
2026-08-24301K572K52.6%220
2026-08-21192K443K43.3%125
2026-08-20329K557K59.0%3,100
2026-08-19469K779K60.1%0
2026-08-18301K471K64.0%0
2026-08-17216K397K54.4%0
2026-08-14222K382K58.1%0
2026-08-13527K924K57.0%0
2026-08-12293K522K56.3%0
2026-08-11786K1000K78.6%0
2026-08-10411K653K62.9%0
2026-08-07612K1.3M48.2%1,100
2026-08-06974K1.9M52.5%0
2026-08-05720K1.4M52.5%116
2026-08-04518K872K59.4%11
2026-08-03320K848K37.8%376
2026-07-31235K407K57.8%0

Fails to deliver

SEC, by settlement date. JSON

As of 22 July 2026, the fails-to-deliver balance in ADMA is 384 shares, down 1,378 shares over the last settlement date. Over the last 47 readings it ranged from 5 shares (1 July 2026) to 261,276 shares (18 September 2025). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-07-22384$8.59$3K
2026-07-201,762$8.71$15K
2026-07-178,863$8.81$78K
2026-07-154,533$8.87$40K
2026-07-015$8.37$42
2026-06-3020,721$8.37$173K
2026-06-255,198$8.70$45K
2026-06-245,449$8.69$47K
2026-06-18477$8.42$4K
2026-06-121,597$8.32$13K
2026-06-0979$8.06$637
2026-06-0840,067$7.97$319K
2026-06-01444$7.98$4K
2026-04-283,237$10.93$35K
2026-04-23600$10.95$7K
2026-04-2015,481$11.01$170K
2026-04-081,638$9.26$15K
2026-04-07316$9.28$3K
2026-03-264,400$9.63$42K
2026-03-1738$15.84$602
2026-03-1636,705$15.15$556K
2026-02-27265$15.18$4K
2026-02-237,752$16.10$125K
2026-02-1230,169$16.28$491K
2026-02-09397$16.43$7K
2026-02-042,256$17.52$40K
2026-01-1586,476$18.28$1.6M
2026-01-1374,547$17.93$1.3M
2025-12-22625$19.58$12K
2025-12-187,480$18.83$141K

Insider trades

SEC Form 4, newest first, 50 of 78 shown. JSON

No open-market insider trades were reported for ADMA in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) on 2026-07-24.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-07-24Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceTax withholding3K$8.37$27K443K
2026-07-16Kohler TerryCFO and TreasurerGrant85K$0.00$0143K
2026-05-27Grossman Jerrold Bn/aBuy6K$7.91$51K520K
2026-05-12Grossman Jerrold Bn/aBuy13K$8.01$100K514K
2026-05-11Grossman Jerrold Bn/aBuy13K$8.01$100K501K
2026-04-01Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceTax withholding20K$9.11$185K446K
2026-03-17Guiheen Lawrence P.n/aGift30K$0.00$0106K
2026-03-16Grossman Adam SPresident and CEOSell6K$15.16$91K2.1M
2026-03-16Grossman Adam SPresident and CEOSell15K$15.16$227K2.1M
2026-03-16Grossman Adam SPresident and CEOOption exercise15K$5.40$81K2.1M
2026-03-13Guiheen Lawrence P.n/aOption exercise30K$3.66$110K136K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceSell10K$15.63$158K467K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise2K$1.55$3K477K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise2K$2.35$4K475K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise3K$2.83$7K473K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise1K$4.31$5K470K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise3K$5.00$13K469K
2026-03-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceJ91K$0.00$0467K
2026-03-07Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceTax withholding4K$15.39$65K558K
2026-03-07Grossman Adam SPresident and CEOTax withholding30K$15.39$454K2.1M
2026-03-06ELMS STEVEn/aBuy7K$15.39$108K2.0M
2026-03-06Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceTax withholding10K$15.39$155K562K
2026-03-06Grossman Adam SPresident and CEOTax withholding56K$15.39$869K2.1M
2026-03-05ELMS STEVEn/aBuy7K$15.67$110K2.0M
2026-02-26Grossman Adam SPresident and CEOTax withholding55K$15.18$833K2.2M
2026-02-19Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceTax withholding8K$16.32$133K572K
2026-02-19Grossman Adam SPresident and CEOTax withholding25K$16.32$405K2.3M
2026-02-19Tade Brad L.CFO and TreasurerTax withholding6K$16.32$106K233K
2026-02-17Grossman Adam SPresident and CEOSell6K$16.08$96K2.3M
2026-02-17Grossman Adam SPresident and CEOSell15K$16.08$241K2.3M
2026-02-17Grossman Adam SPresident and CEOOption exercise15K$5.40$81K2.3M
2026-02-09Grossman Jerrold Bn/aGrant11K$0.00$0489K
2026-02-09Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceGrant92K$0.00$0580K
2026-02-09Grossman Adam SPresident and CEOGrant283K$0.00$02.3M
2026-02-09KWON YOUNGn/aGrant11K$0.00$0263K
2026-02-09FINGER ALISON CECILYn/aGrant11K$0.00$046K
2026-02-09Salas Eduardo Renen/aGrant11K$0.00$022K
2026-02-09Guiheen Lawrence P.n/aGrant11K$0.00$0106K
2026-02-09ELMS STEVEn/aGrant11K$0.00$098K
2025-12-15Grossman Adam SPresident and CEOSell6K$19.79$119K2.0M
2025-12-15Grossman Adam SPresident and CEOSell15K$19.79$297K2.0M
2025-12-15Grossman Adam SPresident and CEOOption exercise15K$5.40$81K2.0M
2025-11-19Grossman Adam SPresident and CEOSell6K$16.00$96K2.0M
2025-11-19Grossman Adam SPresident and CEOSell15K$16.00$240K2.0M
2025-11-19Grossman Adam SPresident and CEOOption exercise15K$5.40$81K2.0M
2025-10-24Grossman Adam SPresident and CEOSell6K$16.00$96K2.0M
2025-10-24Grossman Adam SPresident and CEOSell15K$16.00$240K2.0M
2025-10-24Grossman Adam SPresident and CEOOption exercise15K$5.40$81K2.0M
2025-09-15Grossman Adam SPresident and CEOSell6K$16.13$97K2.0M
2025-09-15Grossman Adam SPresident and CEOSell15K$16.13$242K2.0M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

Large holders (13D and 13G)

One row per reporting person, newest filing first. JSON

2 holders above 5% have filed on ADMA, all on Schedule 13G (passive). The largest reported stake is STATE STREET CORPORATION at 7.4% of the class (17,116,022 shares), filed 2026-08-07 for an event on 2026-06-30.

FiledFormHolderSharesOf classEvent
2026-08-0713GSTATE STREET CORPORATIONparent holding company17.1M7.4%2026-06-30
2026-08-0713GSSGA FUNDS MANAGEMENT, INC.investment adviser11.6M5.0%2026-06-30

13F holders

Tracked managers holding ADMA at their latest 13F. JSON

9 of the 30 tracked managers held ADMA at their latest 13F, $133.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $44.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 5 cut.

FundQuarterSharesValueOf portfolioChange in shares
D. E. Shaw & Co.2026-06-305.3M$44.1M0.02%+4.7M
Duquesne Family Office2026-06-302.8M$23.3M0.45%+1.2M
Two Sigma Investments2026-06-302.0M$16.9M0.01%-72K
Citadel Advisors2026-06-301.6M$13.6M0.00%-4.6M
AQR Capital Management2026-06-301.5M$12.8M0.00%+1.0M
Millennium Management2026-06-301.2M$9.7M0.00%+385K
Renaissance Technologies2026-06-30653K$5.5M0.01%-610K
Point72 Asset Management2026-06-30499K$4.2M0.00%-2.8M
Bridgewater Associates2026-06-30401K$3.4M0.01%-71K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 2026 (quarter ended 2026-06-30) ADMA BIOLOGICS, INC. reported revenue of $124.4M, up 2.0% from the same quarter a year earlier, and net income of $37.8M (0.16 diluted EPS). In FY 2025 it generated $50.4M of operating cash flow and spent $31.9M on buybacks. As of 2026-06-30, cash was $136.0M against $196.6M of debt.

Cash
$136.0M
Debt
$196.6M
Equity
$408.2M
Total assets
$684.2M
Shares outstanding
223,984,680

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q2 20262026-06-30$124.4M$37.8M30.4%0.16
Q1 20262026-03-31$114.5M$45.3M39.6%0.19
Q4 2025derived2025-12-31$139.2Mn/an/an/a
Q3 20252025-09-30$134.2M$36.4M27.1%0.15
Q2 20252025-06-30$122.0M$34.2M28.1%0.14
Q1 20252025-03-31$114.8M$26.9M23.4%0.11
Q4 2024derived2024-12-31$117.5Mn/an/an/a
Q3 20242024-09-30$119.8M$35.9M30.0%0.15

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$510.2Mn/a$50.4M$22.6M$31.9Mn/a
FY 20242024-12-31$426.5Mn/a$118.7M$8.2M$0n/a
FY 20232023-12-31$258.2Mn/a$8.8M$4.8M$0n/a
FY 20222022-12-31$154.1Mn/a-$59.5M$13.9Mn/an/a
FY 20212021-12-31$80.9Mn/a-$112.4M$13.5Mn/an/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.

What this page is

ADMA BIOLOGICS, INC. in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.

This page follows ADMA BIOLOGICS, INC. (ADMA), SEC CIK 1368514, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and method

Short interest
FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-07-22.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-07.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials
SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Insider trades
SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-07-24.JSON and CSV
Company record
EDGAR filing index for CIK 1368514Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
30 requests a minute without a key, 120 a minute with a key from a free account.

Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 09:50 UTC.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as biological products, (no diagnostic substances)

Datasets

Frequently Asked Questions

How much of ADMA is sold short?
22,683,647 shares were held short at the 2026-08-14 settlement, 8.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ADMA's daily short volume?
On 2026-09-11, 388,746 of the 662,705 ADMA shares reported to FINRA were sold short, 58.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ADMA have fails to deliver?
The SEC's latest file shows 384 ADMA shares failed to deliver at settlement 2026-07-22. Fails are reported per settlement date and published twice a month with a lag.
Are ADMA insiders buying or selling?
No open-market insider trades were reported for ADMA in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) on 2026-07-24.
Who owns more than 5% of ADMA?
2 holders above 5% have filed on ADMA, all on Schedule 13G (passive). The largest reported stake is STATE STREET CORPORATION at 7.4% of the class (17,116,022 shares), filed 2026-08-07 for an event on 2026-06-30.
What did ADMA report last quarter?
In Q2 2026 (quarter ended 2026-06-30) ADMA BIOLOGICS, INC. reported revenue of $124.4M, up 2.0% from the same quarter a year earlier, and net income of $37.8M (0.16 diluted EPS). In FY 2025 it generated $50.4M of operating cash flow and spent $31.9M on buybacks. As of 2026-06-30, cash was $136.0M against $196.6M of debt.
Which funds hold ADMA?
9 of the 30 tracked managers held ADMA at their latest 13F, $133.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $44.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 5 cut.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.